Fate of Trump’s 11th hour drug price rules uncertain

If they withstand withering legal challenges from the biopharmaceutical industry, hospitals and medical groups, and overcome steep logistic obstacles, rules released by the Trump administration Friday could reshape the U.S. drug pricing landscape. The Trump administration has not had much success in defending controversial regulatory policies from legal assaults.

At a White House press conference, President Donald Trump announced a final interim rule  “most favored nation” (MFN) that caps Medicare Part B drug reimbursement for 50 drugs at the lowest price paid by any developed country. The Trump administration estimates that the rule would yield savings to taxpayers, and reduced drug company revenues, of more than $85 billion over seven years...